KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Asset Writedowns and Impairment (2021 - 2025)

Historic Asset Writedowns and Impairment for Dynavax Technologies (DVAX) over the last 4 years, with Q3 2025 value amounting to -$338000.0.

  • Dynavax Technologies' Asset Writedowns and Impairment changed N/A to -$338000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 32169.23%. This contributed to the annual value of $3.1 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Dynavax Technologies' Asset Writedowns and Impairment is -$338000.0.
  • In the past 5 years, Dynavax Technologies' Asset Writedowns and Impairment ranged from a high of $19.8 million in Q4 2022 and a low of -$338000.0 during Q3 2025
  • Moreover, its 4-year median value for Asset Writedowns and Impairment was $2.2 million (2021), whereas its average is $4.9 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 66518.55% in 2022, then skyrocketed by 20584.62% in 2025.
  • Over the past 4 years, Dynavax Technologies' Asset Writedowns and Impairment (Quarter) stood at $2.6 million in 2021, then skyrocketed by 665.19% to $19.8 million in 2022, then plummeted by 90.69% to $1.8 million in 2024, then plummeted by 118.33% to -$338000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$338000.0 for Q3 2025, versus $4.0 million for Q1 2025 and $1.8 million for Q4 2024.